Malaria is a persistent illness with a great public health concern. To combat this fatal disease, developing effective antimalarial medications has become a necessity. In the present study, we described the actinomycetes associated with the Red Sea soft coral Nephthea sp. and isolated a strain that was sub-cultured in three different media (M1, ISP2, and OLIGO). Actinomycete isolate’s phylogenetic analysis of the 16S rRNA gene revealed that it belongs to the genus Rhodococcus. In vitro screening of the antimalarial activity for three extracts against Plasmodium falciparum was carried out. Non-targeted metabolomics for the chemical characterization of the isolated actinomycete species UA111 derived extracts were employed using high-resolution liquid chromatography–mass spectrometry (LC-HR-MS) for dereplication purposes. Additionally, statistical analysis of the vast LC-MS data was performed using MetaboAnalyst 5.0. Finally, an in silico analysis was conducted to investigate the potential chemical compounds that could be the source of the antimalarial potential. The results revealed that ISP2 media extract is the most effective against Plasmodium falciparum, according to antimalarial screening (IC₅₀ 8.5 µg/mL), in contrast, OLIGO media extract was inactive. LC-HRMS-based metabolomics identified a range of metabolites, mainly alkaloids, from the genus Rhodococcus. On the other hand, multivariate analysis showed chemical diversity between the analyzed samples, with ISP2 extract being optimal. The docking analysis was able to anticipate the various patterns of interaction of the annotated compounds with three malarial protein targets (P. falciparum kinase, P. falciparum cytochrome bc1 complex, and P. falciparum lysyl-tRNA synthetase). Among all of the test compounds, perlolyrine (11) and 3097-B2 (12) displayed the best docking profiles. In conclusion, this work demonstrated the value of the established method for the metabolic profiling of marine actinomycetes using the data from liquid chromatography–mass spectrometry (LC-MS), which helps to streamline the difficult isolation stages required for their chemical characterization. In addition, the antimalarial efficacy of this strain has intriguing implications for future pharmaceutical development.

The emergence of multidrug-resistant bacterial infections is a major global public health concern. Human health is in danger from microorganisms that have developed resistance to currently used drugs. Honey is well known for its significant activity against antibiotic-resistant bacteria. In this study, the antibacterial properties of honey from various botanical sources in Saudi Arabia against seven significant nosocomial and foodborne pathogens were investigated. The physicochemical properties of four Saudi honey samples—aloe honey (HO1) (Aloe vera L.), anise honey (HO2) (Pimpinella anisum L.), moringa honey (HO4) (Moringa oleifera Lam.), and acacia honey (HO5) (Acacia sp.)—were examined. In addition, they were screened for antibacterial activity against ESKAPE pathogens (Enterobacter faecalis, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella Typhimurium, Escherichia coli, and Enterobacter sp.) and anti-biofilm activity against four pathogenic bacteria strains: S. aureus, P. aeruginosa, S. typhimurium, and E. coli. ¹H NMR profiling and multivariate analysis (PCA and PLS-DA) were performed. Aloe honey (HO1) was the most distinct sample based on MVDA and its antibacterial activity, and it exhibited anti-biofilm activity against most biofilm-forming microorganisms. Its metabolic profile was deduced using LC-MS, and the resulting annotated compounds were docked against several β-lactamase enzyme classes. The results reveal the potential of honey-derived compounds to inhibit β-lactamases due to the presence of gallic acid hexoside and rosmarinic acid, suggesting their potential as competitive inhibitors. Our findings suggest that further honey antibacterial compounds could offer a novel approach to overcoming antibiotic resistance by targeting and inhibiting β-lactamase enzymes.